Physician profile
James Patterson
NPI 1871579706
$4,476.54
in general payments reported to CMS, 2019-2025
34 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $224 · 2021: $219 · 2022: $605 · 2023: $698 · 2024: $1,065 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,814 · Education: $30.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.36 |
| Education | $30.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,423.87 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $844.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $234.59 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.23 | 2020-2024 | Takhzyro |
| Astellas Pharma US INC | $170.61 | 2019-2023 | Veozah |
| Otsuka America Pharmaceutical, INC. | $161.37 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $144.24 | 2024-2025 | Fanapt, Hetlioz |
| Dexcom, INC. | $131.50 | 2022-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $109.67 | 2020-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.50 | 2022-2024 | Caplyta |
| Lundbeck LLC | $94.34 | 2024-2025 | Rexulti |
| Optos, INC. | $92.08 | 2019 | |
| Axsome Therapeutics, INC. | $70.41 | 2024-2025 | Auvelity |
| Abbott Laboratories | $65.40 | 2022-2025 | Freestyle Libre |
| Sunovion Pharmaceuticals INC. | $59.75 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.98 | 2022 | |
| Amgen INC. | $55.21 | 2019-2025 | Otezla, Repatha |
| Biocryst US Sales Co., LLC | $54.01 | 2024-2025 | Orladeyo, Orladeyo |
| Novo Nordisk INC | $51.80 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.68 | 2019-2025 | Xifaxan |
| Allergan, INC. | $40.36 | 2020 | |
| Glaxosmithkline, LLC. | $36.78 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $32.78 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.89 | 2022 | |
| Lilly USA, LLC | $31.63 | 2025 | Zepbound, Mounjaro |
| Inspire Medical Systems, INC. | $27.75 | 2024 | Inspire |
| Neurocrine Biosciences, INC. | $23.47 | 2023 | Ingrezza |
| Exact Sciences Corporation | $18.28 | 2025 | |
| Boston Scientific Corporation | $16.26 | 2019 | |
| Electromed, INC. | $15.39 | 2025 | Smartvest |
| Eisai INC. | $14.88 | 2023 | |
| Myriad Genetic Laboratories, INC. | $13.39 | 2024 | Myrisk |
| Phathom Pharmaceuticals, INC. | $13.37 | 2025 | Voquezna |
| Shire North American Group INC | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.